Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3443488 | 1.00 | HSD11B1 (0.53) | HSD11B1HCRTR1HCRTR2EP300CREBBP | |
| SCHEMBL3443484 | 1.00 | HSD11B1 (0.53) | HSD11B1HCRTR1HCRTR2EP300CREBBP | |
| SCHEMBL3453630 | 0.90 | HSD11B1 (0.51) | HSD11B1EP300CREBBP | |
| SCHEMBL3447833 | 0.90 | HSD11B1 (0.63) | HSD11B1 | |
| SCHEMBL3447831 | 0.90 | HSD11B1 (0.63) | HSD11B1 | |
| SCHEMBL13106596 | 0.89 | HSD11B1 (0.50) | HSD11B1EP300CREBBP | |
| SCHEMBL6273925 | 0.89 | HSD11B1 (0.50) | HSD11B1EP300CREBBP | |
| SCHEMBL3444028 | 0.87 | HSD11B1 (0.52) | HSD11B1EP300CREBBP | |
| SCHEMBL4509406 | 0.85 | HSD11B1 (0.52) | HSD11B1 | |
| SCHEMBL4505869 | 0.85 | HSD11B1 (0.52) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-7517892-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517892-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517892-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7294637-B2 | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter | SEPRACOR, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294637-B2 | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter | SEPRACOR, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294637-B2 | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter | SEPRACOR, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7132551-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2006-11-07 | — | — | US | disclosed |
| WO-2005077463-A2 | LIGAND FOR A MONOAMINE RECEPTOR OR TRANSPORTER FOR TREATING ADDICTION OR DEPENDENCE | SEPRACOR INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | SEPRACOR, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | AQUILA BRIAN M (US) | 2004-04-22 | — | — | US | disclosed |
| EP-1318988-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | Sepracor, Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-03-13 | — | — | US | disclosed |
| WO-2002022572-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | PNMT, TAAR1, OPRL1 | HSD11B1 4177/4885HCRTR1 17/4885HCRTR2 24/4885 |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | HSD11B1 721/4885HCRTR1 53/4885HCRTR2 45/4885 |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | HSD11B1 721/4885HCRTR1 53/4885HCRTR2 45/4885 |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | SLC6A2, OPRL1, SLC18A2 | HSD11B1 721/4885HCRTR1 53/4885HCRTR2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.